-
1081
Dynamic nanoassemblies derived from small-molecule homodimeric prodrugs for in situ drug activation and safe osteosarcoma treatment
Published 2023-08-01“…In a preclinical orthotopic model of human osteosarcomas, nanoparticle administration exhibited durable antitumor efficacy. …”
Get full text
Article -
1082
Pyroptosis-Related Gene Signature Predicts Prognosis and Response to Immunotherapy and Medication in Pediatric and Young Adult Osteosarcoma Patients
Published 2024-01-01“…A nomogram model for predicting OS of osteosarcoma patients was constructed. Single-cell RNA-sequencing data display the expression patterns of the hub PRGs. …”
Get full text
Article -
1083
A deep learning algorithm with good prediction efficacy for cancer-specific survival in osteosarcoma: A retrospective study.
Published 2023-01-01“…<h4>Objective</h4>Successful prognosis is crucial for the management and treatment of osteosarcoma (OSC). This study aimed to predict the cancer-specific survival rate in patients with OSC using deep learning algorithms and classical Cox proportional hazard models to provide data to support individualized treatment of patients with OSC.…”
Get full text
Article -
1084
Anti-osteosarcoma trimodal synergistic therapy using NiFe-LDH and MXene nanocomposite for enhanced biocompatibility and efficacy
Published 2024-03-01Subjects: “…Osteosarcoma…”
Get full text
Article -
1085
Effect of co‐medications and potential risk factors of high‐dose methotrexate‐mediated acute hepatotoxicity in patients with osteosarcoma
Published 2023-06-01Subjects: Get full text
Article -
1086
-
1087
MAT2A inhibits the ferroptosis in osteosarcoma progression regulated by miR-26b-5p
Published 2023-08-01Subjects: “…Osteosarcoma…”
Get full text
Article -
1088
TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling
Published 2023-08-01“…Abstract Osteosarcoma is a highly aggressive malignant tumor that is common in the pediatric population and has a high rate of disability and mortality. …”
Get full text
Article -
1089
-
1090
Highly active selenium nanotherapeutics combined with metformin to achieve synergistic sensitizing effect on NK cells for osteosarcoma therapy
Published 2022-06-01“…Moreover, it provides a multidrug strategy to improve immune cell function in practical applications, especially for synergistic immunotherapy of osteosarcoma.…”
Get full text
Article -
1091
Development of the Osteosarcoma Lung Nodules Detection Model Based on SSD-VGG16 and Competency Comparing With Traditional Method
Published 2022-01-01Subjects: Get full text
Article -
1092
CD248 promotes migration and metastasis of osteosarcoma through ITGB1-mediated FAK-paxillin pathway activation
Published 2023-03-01Subjects: Get full text
Article -
1093
Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma
Published 2024-01-01Subjects: “…Osteosarcoma…”
Get full text
Article -
1094
Chemical bonding of Epigallocatechin-3-gallate to the surface of nano-hydroxyapatite to enhance its biological activity for anti-osteosarcoma
Published 2023-01-01Subjects: “…Osteosarcoma…”
Get full text
Article -
1095
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Published 2015“…Osteosarcoma is the most common primary bone tumor, yet there have been no substantial advances in treatment or survival in three decades. …”
Get full text
Article -
1096
Sequence analysis of cell-free DNA derived from cultured human bone osteosarcoma (143B) cells
Published 2018Journal article -
1097
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
Published 2007“…However, unlike most cancers, many osteosarcomas are resistant to TRAIL. To investigate this resistance, we characterized the response of MG-63 osteosarcoma cells and hPOB-tert osteoblast-like cells to TRAIL and agonist antibodies to death receptor 4 (DR4) and death receptor 5 (DR5). …”
Journal article -
1098
Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions
Published 2017“… <p><b>Background:</b></p> <p>VS38c is a monoclonal antibody that recognises a rough endoplasmic reticulum (rER) intracellular antigen termed cytoskeleton-linking membrane protein 63. rER is typically found in viable tumour cells and is abundant in osteosarcoma cells. The aim of this study was to determine the diagnostic and prognostic utility of VS38c in the histological assessment of osteosarcoma and other bone tumours/tumour-like leisons. …”
Journal article -
1099
Ribozyme mediated down-regulation of thrombospondin receptor CD36 inhibits the growth of the human osteosarcoma cell line.
Published 2004“…The growth of the osteosarcoma cell line HOS may be regulated by autocrine or paracrine loop TSP1 and CD36.…”
Journal article -
1100